Table S3 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
Year: 2023
Type: other
Abstract: Table S3 shows grade {greater than or equal to}3 adverse events (regardless of relationship to study drug) in {greater than or equal to}2 patients in total phase 1 population
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361817092
